Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant

Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

from News Medical Medical Research News Feed https://ift.tt/2KCRcl9